MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Balance Sheets Overview
Debt to Asset Ratio
4.79%
Unit: Thousand (K) dollars
Assets Breakdown
Cash and cash equivalents
Incentive and tax receivables
Prepaid expenses and other curre...
Liabilities Breakdown
Additional paid-in capital
Accumulated deficit
Accrued liabilities - note 3
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Balance Sheets
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
131,749
102,577
101,164
Incentive and tax receivables
844
809
820
Prepaid expenses and other current assets
396
429
448
Total assets
132,989
103,815
102,432
Deferred grant income - note 4
-
-
805
Accounts payable
2,639
4,249
6,740
Accrued liabilities - note 3
2,927
3,892
3,929
Deferred grant income - note 4
805
805
-
Capital stock authorized10,000,000 preferred stock, par value 0.001 per share
-
-
0
Total liabilities
6,371
8,946
11,474
92,671,758 common shares (september 30, 2025 - 86,668,521)
93
87
85
Additional paid-in capital
514,654
477,230
463,494
Accumulated deficit
-388,129
-382,448
-372,621
Total stockholders equity
126,618
94,869
90,958
Total liabilities and stockholders equity
132,989
103,815
102,432
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Cash and cash
equivalents
$131,749K
Incentive and tax
receivables
$844K
Prepaid expenses and
other current assets
$396K
Total assets
$132,989K
Total liabilities and
stockholders equity
$132,989K
Total stockholders
equity
$126,618K
Total liabilities
$6,371K
Accumulated deficit
-$388,129K
Additional paid-in capital
$514,654K
Accrued liabilities -
note 3
$2,927K
Accounts payable
$2,639K
Deferred grant income -
note 4
$805K
92,671,758 common shares
(september 30, 2025 -...
$93K
Buy us a coffee
ANAVEX LIFE SCIENCES CORP. (AVXL)
ANAVEX LIFE SCIENCES CORP. (AVXL)